Details of the Drug

General Information of Drug (ID: DMN4H2O)

Drug Name
Zithromax
Synonyms
azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955
Indication
Disease Entry ICD 11 Status REF
Syphilis infection 1A6Z Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 749
Topological Polar Surface Area (xlogp) 4
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [2]
Bioavailability
The bioavailability of drug is 70% [2]
Clearance
The clearance of drug is 630 mL/min [3]
Elimination
Biliary excretion of azithromycin, primarily as unchanged drug, is a major route of elimination [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 68 hours [4]
Vd
The volume of distribution (Vd) of drug is 31.1 L/kg [5]
Chemical Identifiers
Formula
C38H72N2O12
IUPAC Name
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
Canonical SMILES
CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
InChI
InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChIKey
MQTOSJVFKKJCRP-BICOPXKESA-N
Cross-matching ID
PubChem CID
447043
ChEBI ID
CHEBI:2955
CAS Number
83905-01-5
DrugBank ID
DB00207
TTD ID
D03HJK
INTEDE ID
DR0168
ACDINA ID
D00056

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Modulator [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Zithromax (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Moderate Decreased metabolism of Zithromax caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [26]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Thioguanine. Acute myeloid leukaemia [2A60] [27]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Zithromax and Ivosidenib. Acute myeloid leukaemia [2A60] [28]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Zithromax and Midostaurin. Acute myeloid leukaemia [2A60] [29]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Zithromax and Idarubicin. Acute myeloid leukaemia [2A60] [29]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Zithromax and Daunorubicin. Acute myeloid leukaemia [2A60] [29]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Gilteritinib. Acute myeloid leukaemia [2A60] [30]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Zithromax and Oliceridine. Acute pain [MG31] [29]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Zithromax and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [29]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Tacrine. Alzheimer disease [8A20] [29]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Galantamine. Alzheimer disease [8A20] [29]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Rivastigmine. Alzheimer disease [8A20] [29]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Donepezil. Alzheimer disease [8A20] [29]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Zithromax and Metronidazole. Amoebiasis [1A36] [31]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ranolazine. Angina pectoris [BA40] [32]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Zithromax and Ivabradine. Angina pectoris [BA40] [33]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Zithromax and Bepridil. Angina pectoris [BA40] [29]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Zithromax and Dronedarone. Angina pectoris [BA40] [29]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Zithromax and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [34]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [29]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Zithromax and Promazine. Appearance/behaviour symptom [MB23] [29]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Zithromax and Cilostazol. Arterial occlusive disease [BD40] [29]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Zithromax and Voriconazole. Aspergillosis [1F20] [29]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Zithromax and Posaconazole. Aspergillosis [1F20] [29]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Terbutaline. Asthma [CA23] [35]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Pirbuterol. Asthma [CA23] [35]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Isoetharine. Asthma [CA23] [35]
Aminophylline DML2NIB Moderate Decreased metabolism of Zithromax caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [36]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Formoterol. Asthma [CA23] [35]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [33]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Zithromax and Desipramine. Attention deficit hyperactivity disorder [6A05] [29]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ofloxacin. Bacterial infection [1A00-1C4Z] [37]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [29]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Zithromax and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [29]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Zithromax and Sparfloxacin. Bacterial infection [1A00-1C4Z] [37]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Zithromax and Gemifloxacin. Bacterial infection [1A00-1C4Z] [37]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Norfloxacin. Bacterial infection [1A00-1C4Z] [37]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Zithromax and Levofloxacin. Bacterial infection [1A00-1C4Z] [37]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Zithromax and Moxifloxacin. Bacterial infection [1A00-1C4Z] [38]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Zithromax and Telithromycin. Bacterial infection [1A00-1C4Z] [29]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Zithromax and Retigabine. Behcet disease [4A62] [29]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Zithromax and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [39]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Loperamide. Bowel habit change [ME05] [40]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Zithromax and Eribulin. Breast cancer [2C60-2C6Y] [29]
Talazoparib DM1KS78 Moderate Decreased clearance of Zithromax due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [41]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Tamoxifen. Breast cancer [2C60-2C6Y] [29]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Zithromax and Toremifene. Breast cancer [2C60-2C6Y] [29]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Zithromax and Bosutinib. Breast cancer [2C60-2C6Y] [33]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Zithromax and Grepafloxacin. Bronchitis [CA20] [37]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Zithromax and Sotalol. Cardiac arrhythmia [BC9Z] [29]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Zithromax and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [42]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Olodaterol. Chronic obstructive pulmonary disease [CA22] [35]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Vilanterol. Chronic obstructive pulmonary disease [CA22] [43]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Salmeterol. Chronic obstructive pulmonary disease [CA22] [35]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Indacaterol. Chronic obstructive pulmonary disease [CA22] [35]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Arformoterol. Chronic obstructive pulmonary disease [CA22] [35]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Zithromax and Anisindione. Coagulation defect [3B10] [44]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Zithromax and Oxaliplatin. Colorectal cancer [2B91] [29]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Zithromax and Isoproterenol. Conduction disorder [BC63] [43]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Halothane. Corneal disease [9A76-9A78] [29]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Zithromax and Propofol. Corneal disease [9A76-9A78] [45]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Sevoflurane. Corneal disease [9A76-9A78] [29]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Zithromax and Probucol. Coronary atherosclerosis [BA80] [29]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Zithromax caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [36]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Zithromax and Methadone. Cough [MD12] [29]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Zithromax and Clofazimine. Crohn disease [DD70] [46]
Mycophenolic acid DMU65NK Moderate Altered absorption of Zithromax due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [47]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Zithromax and Mifepristone. Cushing syndrome [5A70] [29]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Zithromax and Pasireotide. Cushing syndrome [5A70] [29]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Zithromax and Osilodrostat. Cushing syndrome [5A70] [33]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Zithromax due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [48]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Zithromax and Sertraline. Depression [6A70-6A7Z] [29]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Zithromax and Trimipramine. Depression [6A70-6A7Z] [29]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Imipramine. Depression [6A70-6A7Z] [29]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Zithromax and Fluoxetine. Depression [6A70-6A7Z] [29]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Nortriptyline. Depression [6A70-6A7Z] [29]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Zithromax and Escitalopram. Depression [6A70-6A7Z] [29]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Zithromax and Clomipramine. Depression [6A70-6A7Z] [29]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Trazodone. Depression [6A70-6A7Z] [49]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Zithromax and Amoxapine. Depression [6A70-6A7Z] [29]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Mirtazapine. Depression [6A70-6A7Z] [50]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Zithromax and Protriptyline. Depression [6A70-6A7Z] [29]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Zithromax and Doxepin. Depression [6A70-6A7Z] [29]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Zithromax and Maprotiline. Depression [6A70-6A7Z] [29]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Zithromax and Citalopram derivative 1. Discovery agent [N.A.] [29]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Zithromax caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [36]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Zithromax and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [29]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Zithromax and Deutetrabenazine. Dystonic disorder [8A02] [51]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ingrezza. Dystonic disorder [8A02] [52]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Cannabidiol. Epileptic encephalopathy [8A62] [33]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Zithromax and Solifenacin. Functional bladder disorder [GC50] [29]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Zithromax and Pentamidine. Fungal infection [1F29-1F2F] [29]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ketoconazole. Fungal infection [1F29-1F2F] [29]
Ripretinib DM958QB Moderate Decreased clearance of Zithromax due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [31]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Zithromax and Sunitinib. Gastrointestinal stromal tumour [2B5B] [29]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Zithromax caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [53]
Digoxin DMQCTIH Moderate Decreased clearance of Zithromax due to the transporter inhibition by Digoxin. Heart failure [BD10-BD1Z] [54]
Digitoxin DMWVIGP Moderate Decreased clearance of Zithromax due to the transporter inhibition by Digitoxin. Heart failure [BD10-BD1Z] [54]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Zithromax due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [55]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Zithromax and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [56]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Zithromax and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [57]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Zithromax and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [58]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Zithromax and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [29]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Zithromax and Mipomersen. Hyper-lipoproteinaemia [5C80] [59]
Aliskiren DM1BV7W Moderate Decreased clearance of Zithromax due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [29]
Quinapril DMR8H31 Moderate Decreased absorption of Zithromax due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [33]
Berotralstat DMWA2DZ Major Decreased clearance of Zithromax due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [60]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Polyethylene glycol. Irritable bowel syndrome [DD91] [33]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Phenolphthalein. Irritable bowel syndrome [DD91] [29]
Naloxegol DML0B41 Minor Decreased clearance of Zithromax due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [61]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Methotrexate. Leukaemia [2A60-2B33] [33]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Zithromax and Ceritinib. Lung cancer [2C25] [29]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Zithromax and Osimertinib. Lung cancer [2C25] [62]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Zithromax and Selpercatinib. Lung cancer [2C25] [33]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Zithromax and Lumefantrine. Malaria [1F40-1F45] [31]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Zithromax and Halofantrine. Malaria [1F40-1F45] [63]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Zithromax and Chloroquine. Malaria [1F40-1F45] [64]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Quinine. Malaria [1F40-1F45] [29]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Zithromax and Primaquine. Malaria [1F40-1F45] [29]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [33]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [65]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Idelalisib. Mature B-cell leukaemia [2A82] [66]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Zithromax and Arsenic trioxide. Mature B-cell lymphoma [2A85] [67]
Arry-162 DM1P6FR Moderate Decreased clearance of Zithromax due to the transporter inhibition by Arry-162. Melanoma [2C30] [31]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Zithromax and Vemurafenib. Melanoma [2C30] [29]
Methysergide DM1EF73 Moderate Decreased metabolism of Zithromax caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [26]
Dihydroergotamine DM5IKUF Moderate Decreased metabolism of Zithromax caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [53]
Ubrogepant DM749I3 Moderate Decreased clearance of Zithromax due to the transporter inhibition by Ubrogepant. Migraine [8A80] [68]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Zithromax and Panobinostat. Multiple myeloma [2A83] [69]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Thalidomide. Multiple myeloma [2A83] [31]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Zithromax and Siponimod. Multiple sclerosis [8A40] [31]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Zithromax and Fingolimod. Multiple sclerosis [8A40] [29]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Zithromax and Ozanimod. Multiple sclerosis [8A40] [70]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Zithromax and Romidepsin. Mycosis fungoides [2B01] [29]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Zithromax and Nilotinib. Myeloproliferative neoplasm [2A20] [29]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Zithromax and Dasatinib. Myeloproliferative neoplasm [2A20] [71]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Zithromax and Droperidol. Nausea/vomiting [MD90] [29]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Zithromax and Prochlorperazine. Nausea/vomiting [MD90] [29]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Zithromax and Promethazine. Nausea/vomiting [MD90] [29]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Zithromax and Dolasetron. Nausea/vomiting [MD90] [29]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Zithromax and Ondansetron. Nausea/vomiting [MD90] [29]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Zithromax and Levomethadyl Acetate. Opioid use disorder [6C43] [33]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Lofexidine. Opioid use disorder [6C43] [29]
S-297995 DM26IH8 Moderate Decreased clearance of Zithromax due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [33]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Rucaparib. Ovarian cancer [2C73] [29]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Zithromax and Dextropropoxyphene. Pain [MG30-MG3Z] [72]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Zithromax and Buprenorphine. Pain [MG30-MG3Z] [29]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Zithromax and Triclabendazole. Parasitic worm infestation [1F90] [29]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Zithromax and Pimavanserin. Parkinsonism [8A00] [73]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Apomorphine. Parkinsonism [8A00] [29]
Cabergoline DMQ4HIN Moderate Decreased metabolism of Zithromax caused by Cabergoline mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [53]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Zithromax and Macimorelin. Pituitary gland disorder [5A60-5A61] [74]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Zithromax and Lefamulin. Pneumonia [CA40] [75]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Zithromax caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [26]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Ritodrine. Preterm labour/delivery [JB00] [35]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Zithromax and Degarelix. Prostate cancer [2C82] [33]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Zithromax and ABIRATERONE. Prostate cancer [2C82] [33]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Zithromax and Nilutamide. Prostate cancer [2C82] [33]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Zithromax and Enzalutamide. Prostate cancer [2C82] [33]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Zithromax and Flutamide. Prostate cancer [2C82] [33]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Zithromax and Relugolix. Prostate cancer [2C82] [76]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Zithromax and Bicalutamide. Prostate cancer [2C82] [33]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Zithromax and Levomepromazine. Psychotic disorder [6A20-6A25] [29]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Zithromax and Fluphenazine. Psychotic disorder [6A20-6A25] [29]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Zithromax and Triflupromazine. Psychotic disorder [6A20-6A25] [29]
Riociguat DMXBLMP Moderate Decreased clearance of Zithromax due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [31]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Zithromax and Gatifloxacin. Respiratory infection [CA07-CA4Z] [38]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Zithromax and Leflunomide. Rheumatoid arthritis [FA20] [29]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Zithromax and Quetiapine. Schizophrenia [6A20] [29]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Zithromax and Mesoridazine. Schizophrenia [6A20] [29]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Zithromax and Thioridazine. Schizophrenia [6A20] [29]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Zithromax and Aripiprazole. Schizophrenia [6A20] [31]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Zithromax and Iloperidone. Schizophrenia [6A20] [29]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Zithromax and Paliperidone. Schizophrenia [6A20] [29]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Zithromax and Haloperidol. Schizophrenia [6A20] [29]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Zithromax and Perphenazine. Schizophrenia [6A20] [29]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Chlorpromazine. Schizophrenia [6A20] [29]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Zithromax and Trifluoperazine. Schizophrenia [6A20] [29]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Zithromax and Ziprasidone. Schizophrenia [6A20] [29]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Zithromax and Risperidone. Schizophrenia [6A20] [29]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Zithromax and Olanzapine. Schizophrenia [6A20] [31]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Zithromax and Amisulpride. Schizophrenia [6A20] [77]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Asenapine. Schizophrenia [6A20] [29]
Pimozide DMW83TP Major Decreased metabolism of Zithromax caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [44]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Vardenafil. Sexual dysfunction [HA00-HA01] [29]
Docetaxel DMDI269 Moderate Decreased clearance of Zithromax due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [78]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [33]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Zithromax and LEE011. Solid tumour/cancer [2A00-2F9Z] [29]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Zithromax and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [29]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Zithromax and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [29]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Zithromax and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [33]
Taxol DMUOT9V Moderate Decreased clearance of Zithromax due to the transporter inhibition by Taxol. Solid tumour/cancer [2A00-2F9Z] [78]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Zithromax and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [29]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Pitolisant. Somnolence [MG42] [29]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Zithromax and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [29]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Zithromax and Naltrexone. Substance abuse [6C40] [79]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Zithromax and Warfarin. Supraventricular tachyarrhythmia [BC81] [44]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Zithromax and Ibutilide. Supraventricular tachyarrhythmia [BC81] [80]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Zithromax and Adenosine. Supraventricular tachyarrhythmia [BC81] [29]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Zithromax due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [81]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Zithromax and Anagrelide. Thrombocytosis [3B63] [29]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of Zithromax and Dicumarol. Thrombosis [DB61-GB90] [82]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Lenvatinib. Thyroid cancer [2D10] [29]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Zithromax and Cabozantinib. Thyroid cancer [2D10] [33]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Zithromax and Papaverine. Tonus and reflex abnormality [MB47] [83]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Zithromax and Tizanidine. Tonus and reflex abnormality [MB47] [29]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Zithromax due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [47]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Zithromax and Tacrolimus. Transplant rejection [NE84] [84]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Zithromax and Astemizole. Vasomotor/allergic rhinitis [CA08] [29]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Zithromax and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [72]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Zithromax and Disopyramide. Ventricular tachyarrhythmia [BC71] [31]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Zithromax and Procainamide. Ventricular tachyarrhythmia [BC71] [29]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Zithromax and Propafenone. Ventricular tachyarrhythmia [BC71] [29]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Zithromax and Flecainide. Ventricular tachyarrhythmia [BC71] [29]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Zithromax and Amiodarone. Ventricular tachyarrhythmia [BC71] [85]
⏷ Show the Full List of 216 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
Caprylic acid E00017 379 Emulsifying agent; Flavoring agent; Surfactant
Carminic acid E00506 10255083 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Magnesium trisilicate E00477 5311266 Glidant
Pigment red 5 E00380 82169 Colorant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Azithromycin 250 mg tablet 250 mg Oral Tablet Oral
Azithromycin 500 mg tablet 500 mg Oral Tablet Oral
Azithromycin 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets
3 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 McMullan BJ, Mostaghim M: Prescribing azithromycin. Aust Prescr. 2015 Jun;38(3):87-9. Epub 2015 Jun 1.
6 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
9 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
10 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
11 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
12 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
13 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
18 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
19 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
20 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
21 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
22 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
23 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
24 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
25 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
26 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
27 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
28 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
29 Canadian Pharmacists Association.
30 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
31 Cerner Multum, Inc. "Australian Product Information.".
32 European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
35 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
36 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
37 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
38 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
39 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
40 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
41 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
45 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
46 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
48 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
49 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
50 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
51 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
52 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
53 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
54 Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
55 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
56 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
57 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
58 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
59 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
60 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
61 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
62 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
63 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
64 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
65 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
66 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
67 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
68 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
69 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
71 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
72 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
73 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
74 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
75 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
76 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
77 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
78 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
79 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
80 Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72. [PMID: 8306730]
81 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
82 Beckey NP, Parra D, Colon A "Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin." Pharmacotherapy 20 (2000): 1055-9. [PMID: 10999497]
83 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
84 Ibrahim RB, Abella EM, Chandrasekar PH "Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation." Ann Pharmacother 36 (2002): 1971-1972. [PMID: 12452763]
85 Nattel S, Ranger S, Talajic M, et al "Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism." Am J Med 89 (1990): 235-8. [PMID: 2382671]